Yamamoto H, Sugihara N
Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Hiroshima, Japan.
Toxicol Appl Pharmacol. 1987 Dec;91(3):461-8. doi: 10.1016/0041-008x(87)90067-6.
An investigation of the mechanism of development of hepatic encephalopathy induced by CCl4 was performed in rats. CCl4 (1.0 ml/kg three times per week for over 10 weeks) caused hepatic encephalopathy in 80% of the treated rats. Accompanying the hepatic encephalopathy were hematemesis, abdominal dropsy, and hyperammonemia, conditions observed in hepatic coma patients. The blood ammonia levels were tremendously increased in only those rats with hepatic encephalopathy. Hepatic activities of carbamylphosphate synthetase (CPS) and argininosuccinate synthetase (ASS), important enzymes of the urea cycle, were significantly inhibited by CCl4. However, the causality between the inhibition of CPS or ASS activity and the increase in blood ammonia levels was not observed. On the other hand, the content of ATP, which is a substrate of CPS and ASS, was decreased by 60% in liver of rats with hepatic encephalopathy. The activity of Mg2+-ATPase which can decompose hepatic ATP was increased by 60 and 300% in mitochondria and microsomes, respectively, of livers of rats with CCl4-induced encephalopathy. There was a good correlation between the decreased hepatic ATP content and the increased mitochondrial Mg2+-ATPase activity. Furthermore, there was also a good correlation between the increase in blood ammonia levels and the increase in Mg2+-ATPase activity in microsomes. These findings suggest that hyperammonemia, which was produced by the decrease in hepatic content and by the inhibition of CPS and ASS, may play an important role in induction of hepatic encephalopathy.
在大鼠中进行了四氯化碳诱导肝性脑病发病机制的研究。四氯化碳(每周3次,每次1.0 ml/kg,持续10周以上)使80%的受试大鼠发生肝性脑病。伴随肝性脑病出现了呕血、腹水和高氨血症,这些情况在肝昏迷患者中也可见。仅在那些患有肝性脑病的大鼠中血氨水平大幅升高。尿素循环的重要酶氨基甲酰磷酸合成酶(CPS)和精氨酸琥珀酸合成酶(ASS)的肝脏活性被四氯化碳显著抑制。然而,未观察到CPS或ASS活性抑制与血氨水平升高之间的因果关系。另一方面,作为CPS和ASS底物的ATP含量在患有肝性脑病的大鼠肝脏中降低了60%。在四氯化碳诱导的肝性脑病大鼠肝脏的线粒体和微粒体中,可分解肝脏ATP的Mg2+-ATP酶活性分别增加了60%和300%。肝脏ATP含量降低与线粒体Mg2+-ATP酶活性增加之间存在良好的相关性。此外,血氨水平升高与微粒体中Mg2+-ATP酶活性增加之间也存在良好的相关性。这些发现表明,由肝脏含量降低以及CPS和ASS抑制所产生的高氨血症可能在肝性脑病的诱发中起重要作用。